JP2006522062A5 - - Google Patents

Download PDF

Info

Publication number
JP2006522062A5
JP2006522062A5 JP2006504970A JP2006504970A JP2006522062A5 JP 2006522062 A5 JP2006522062 A5 JP 2006522062A5 JP 2006504970 A JP2006504970 A JP 2006504970A JP 2006504970 A JP2006504970 A JP 2006504970A JP 2006522062 A5 JP2006522062 A5 JP 2006522062A5
Authority
JP
Japan
Prior art keywords
methyl
dihydro
benzodiazepine
dioxolo
aminophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006504970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522062A (ja
Filing date
Publication date
Priority claimed from GBGB0307860.7A external-priority patent/GB0307860D0/en
Application filed filed Critical
Publication of JP2006522062A publication Critical patent/JP2006522062A/ja
Publication of JP2006522062A5 publication Critical patent/JP2006522062A5/ja
Pending legal-status Critical Current

Links

JP2006504970A 2003-04-04 2004-04-02 神経学的障害の処置のための抗癲癇剤を含む組み合わせ Pending JP2006522062A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307860.7A GB0307860D0 (en) 2003-04-04 2003-04-04 Organic compounds
PCT/EP2004/003518 WO2004087161A1 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
JP2006522062A JP2006522062A (ja) 2006-09-28
JP2006522062A5 true JP2006522062A5 (enExample) 2007-05-17

Family

ID=9956223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006504970A Pending JP2006522062A (ja) 2003-04-04 2004-04-02 神経学的障害の処置のための抗癲癇剤を含む組み合わせ

Country Status (10)

Country Link
US (1) US20060194766A1 (enExample)
EP (1) EP1620103A1 (enExample)
JP (1) JP2006522062A (enExample)
CN (1) CN100546581C (enExample)
AU (1) AU2004226825B2 (enExample)
BR (1) BRPI0409170A (enExample)
CA (1) CA2521274A1 (enExample)
GB (1) GB0307860D0 (enExample)
MX (1) MXPA05010707A (enExample)
WO (1) WO2004087161A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US20100168174A1 (en) * 2007-07-13 2010-07-01 Eisai R&D Management Co., Ltd. Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain
US20090054414A1 (en) * 2007-07-23 2009-02-26 Synosia Therapeutics Rufinamide for the Treatment of Post-Traumatic Stress Disorder
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
UA128017C2 (uk) 2018-09-28 2024-03-13 Каруна Тереп'Ютікс, Інк. Композиція і спосіб лікування розладу, що послаблюється активацією мускаринових рецепторів (варіанти)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) * 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
GB1028234A (en) * 1964-01-06 1966-05-04 Ici Ltd New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives
AU2929489A (en) * 1987-12-22 1989-07-19 John W. FERKANY Dextrorphan potentiator for anticonvulsant composition and method
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
IT1261808B (it) * 1993-07-06 1996-06-03 Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi
EP0946597B1 (en) * 1996-10-19 2003-08-13 University Of Wales, Bangor Preparation of chemically reactive starch
ID21927A (id) * 1996-10-24 1999-08-12 Novartis Ag Asam aminoalkanafosfonat tersubstitusi
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
CN1265889A (zh) * 1999-03-06 2000-09-13 王学勇 一种治疗癫痫病的药物
YU37602A (sh) * 1999-12-01 2005-07-19 Ucb S.A. Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
KR20050044396A (ko) * 2001-11-12 2005-05-12 노파르티스 아게 정동 및 주의력 장애 및 신경병성 통증 치료용 의약제조에 사용하기 위한 모노히드록시카르바마제핀

Similar Documents

Publication Publication Date Title
RU2326881C2 (ru) Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k)
Summy et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes
EP3626309B1 (en) Lxrbeta agonist for the treatment of cancer
TWI500616B (zh) 新穎之雙環吡啶酮
ES2638850T3 (es) Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos
US20190125745A1 (en) Treatment and diagnosis of cancer
AR072688A1 (es) Nucleosidos y nucleotidos biciclicos como agentes terapeuticos
JP2005504080A5 (enExample)
RU2006107785A (ru) 2, 4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
RU96111418A (ru) ПРОИЗВОДНЫЕ ПИРИМИДИНДИОНА, ПИРИМИДИНТРИОНА, ТРИАЗИНДИОНА, ТЕТРАГИДРОХИНАЗОЛИНДИОНА В КАЧЕСТВЕ АНТАГОНИСТОВ α1 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ
JP2019014758A (ja) デオキシウリジントリホスファターゼ阻害剤
KR20120116925A (ko) 항종양 효과 증강제
JP2004527560A5 (enExample)
JP2006522062A5 (enExample)
AU2011227398A1 (en) Modulators of Hec1 activity and methods therefor
EP1797878A3 (en) Benzothiazole derivatives
TW201936585A (zh) 5-氟尿嘧啶化合物
JP2017526724A5 (enExample)
US20190029984A1 (en) Methods for the treatment of myeloid derived suppressor cells related disorders
JP2013503859A (ja) キナーゼインヒビター、そのプロドラッグ型および治療におけるそれらの使用
JP2009501746A5 (enExample)
CA2460135C (en) Use of pyridazinone compounds as phosphodiesterase iv inhibitors for treating cancer and other diseases
JP2009525292A5 (enExample)
US11571437B2 (en) Methods of treating cancer using PRMT5 inhibitors
BRPI0520451A2 (pt) métodos para tratamento de distúrbios associados a substáncias quìmicas